In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type

Type

Guidance programme 1 selected

Guidance programme

Showing 301 to 310 of 342

TitleTypeExpected publication date
Tarlatamab for treating small-cell lung cancer that has progressed after platinum-based chemotherapy ID6617Technology appraisal guidanceTBC
Taselisib for previously treated ER-positive, HER2-negative, PIK3CA-positive breast cancer in postmenopausal women ID1401Technology appraisal guidanceTBC
Teclistamab with daratumumab for treating relapsed or refractory multiple myeloma after 1 or more therapies [ID6201]Technology appraisal guidance
Telisotuzumab vedotin for treating c-MET overexpressed, EGFR wild-type, non-squamous advanced non-small-cell lung cancer after 1 or more systemic treatments [ID6253]Technology appraisal guidanceTBC
Teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes [ID6259]Technology appraisal guidance
Teprotumumab for treating thyroid eye disease [ID6432]Technology appraisal guidanceTBC
Tezepelumab for treating severe chronic rhinosinusitis with nasal polyps ID6379Technology appraisal guidance
Third molars (impacted) - prophylactic removal [ID898]Technology appraisal guidanceTBC
Tiragolumab with atezolizumab and bevacizumab for untreated unresectable or advanced hepatocellular carcinoma [TSID12238]Technology appraisal guidanceTBC
Tiragolumab with atezolizumab for treating advanced oesophageal squamous cell cancer after chemoradiotherapy [ID6267]Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All